Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells

Oncogene

Volumn 27, Issue 20, 2008, Pages 2810-2822

  Takano, S ^a   Yoshitomi, H ^a   Togawa, A ^a   Sogawa, K ^a   Shida, T ^a   Kimura, F ^a   Shimizu, H ^a   Tomonaga, T ^a   Nomura, F ^a   Miyazaki, M ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Apolipoprotein C 1; Apoptosis; Pancreatic cancer; SELDI TOF MS; Serum marker

Indexed keywords

APOLIPOPROTEIN C1; SMALL INTERFERING RNA;

ADULT; AGED; AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LETHALITY; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PANCREAS RESECTION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADENOCARCINOMA; APOLIPOPROTEIN C-I; APOPTOSIS; CARCINOMA, ADENOSQUAMOUS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 42949166699     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210951     Document Type: Article

References (32)

1. Bardeesy N, Depinho RA. (2002). Pancreatic cancer biology and genetics. Nat Rev 2: 897-909.
2. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 152: 2403-2413.
3. Chen X, Lin J, Kanekura T, Su J, Lin W, Xie H et al. (2006). A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma. Cancer Res 66: 11323-11330.
4. Chen YC, Pohl G, Wang TL, Morin PJ, Risberg B, Kristensen GB et al. (2005). Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res 65: 331-337.
5. Ehmann M, Felix K, Hartmann D, Schnolzer M, Nees M, Vorderwulbecke S et al. (2007). Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 34: 205-214.
6. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. (1992). Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 148: 2207-2216.
7. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez- delCastillo C, Warshaw AL. (2006). Perioperative CA19-9 levels can predict stage and survival in patients with respectable pancreatic adenocarcinoma. J Clin Oncol 24: 2897-2902.
8. Goncalves A, Esterni B, Bertucci F, Sauvan R, Chabannon C, Cubizolles M et al. (2006). Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 25: 981-989.
9. Hannon GJ, Rossi JJ. (2004). Unlocking the potential of the human genome with RNA interference. Nature 431: 371-378.
10. Iacobuzio-Donahue CA, Ryu B, Hruban RH, Kern SE. (2002). Exploring the host desmoplastic response to pancreatic carcinoma. Am J Pathol 160: 91-99.
11. Jemal A, Siegel R, Ward E, Murray T, Xu J, Sumigal C et al. (2006). Cancer statistics, 2006. CA Cancer J Clin 56: 106-130.
12. Lauer SJ, Walker D, Elshourbagy NA, Reardon CA, Wilson BL, Taylor JM. (1988). Two copies of the human apolipoprotein C-I gene are linked closely to the apolipoprotein E gene. J Biol Chem 263: 7277-7286.
13. Melle C, Ernst G, Schimmel B, Bleul A, Thieme H, Kaufmann R et al. (2005). Discovery and identification of à-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology 129: 66-73.
14. Mitsuhashi N, Shimizu H, Ohtsuka M, Wakabayashi Y, Ito H, Kimura F et al. (2003). Angiopoietins and tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 37: 1105-1113.
15. Moore MJ, Goldstein D, Hamm J, Figer A, Hechet JR, Gallinger S et al. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1942-1952.
16. Mutaguchi K, Yasumoto H, Mita K, Matsubara A, Shiina H, Igawa M et al. (2003). Restoration of insulin-like growth factor binding protein-related protein 1 has a tumor-suppressive activity through Induction of apoptosis in human prostate cancer. Cancer Res 63: 7717-7723.
17. Nomura F, Tomonaga T, Sogawa K, Ohashi T, Nezu M, Sunaga M et al. (2004). Identification of novel and downregulated biomarkers for alcoholism by surface enhanced laser desorption/ionization-mass spectrometry. Proteomics 4: 1187-1194.
18. Paradis V, Degos F, Dargere D, Pham N, Belghiti J, Degott C et al. (2005). Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 41: 40-47.
19. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM et al. (2002). Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577.
20. Rhodes J. (1999). Usefulness of novel tumor markers. Ann Oncol 10: 118-121.
21. Rosty C, Christa L, Kuzdzal S, Baldwin WM, Zahurak ML, Carnot F et al. (2002). Identification of hepatocarcinoma-intestine-pancreas/ pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 62: 1868-1875.
22. Ryu B, Jones J, Hollingsworth MA, Hruban RH, Kern SE. (2001). Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers. Cancer Res 61: 1833-1838.
23. Sato N, Fukushima N, Chang R, Matsubayashi H, Goggins M. (2006). Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. Gastroenterology 130: 548-565.
24. Schaefer EJ, Eisenberg S, Levy RI. (1978). Lipoprotein apoproteins metabolism. J Lipid Res 19: 667-687.
25. Shida T, Furuya M, Nikaido T, Hasegawa M, Koda K, Oda K et al. (2006). Sonic hedgehog-Gli1 signaling pathway might become an effective therapeutic target in gastrointestinal neuroendocrine carcinomas. Cancer Biol Ther 5: 1530-1538.
26. Sobin LH, Wittekind CH. (2002). International Union Against Cancer (UICC): TNM Classification of Malignant Tumours, 6th edn. Wiley: New York.
27. Tomonaga T, Matsushita K, Yamaguchi S, Oh-Ishi M, Kodera Y, Maeda T et al. (2004). Identification of altered protein expression and post-translational modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis. Clin Cancer Res 10: 2007-2014.
28. Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES. (2004). Silencing expression of the clusterin/apolipoprotein J gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 64: 1834-1842.
29. Wroblewski MS, Wilson-Grady JT, Martinez MB, Kasthuri RS, McMillan KR, Flood-Urdangarin C et al. (2006). A functional polymorphism of apolipoprotein C1 detected by mass spectrometry. FEBS J 273: 4707-4715.
30. Xiao Z, Adam BL, Cazares LH, Clements MA, Davis JW, Schellhammer PF et al. (2001). Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 61: 6029-6033.
31. Xiao Z, Prieto D, Conrads TP, Veenstra TD, Issaq HJ. (2005). Proteomic patterns: their potential for disease diagnosis. Mol Cell Endocrinol 230: 95-106.
32. Yu KH, Rustgi AK, Blair IA. (2005). Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J Proteome Res 4: 1742-1751.